| Size | Price | |
|---|---|---|
| 5mg | ||
| 10mg | ||
| Other Sizes |
| ln Vitro |
In mouse nucleus accumbens slices, diphenpyraline (10 μM) dramatically reduces dopamine uptake [2].
|
|---|---|
| ln Vivo |
Intraperitoneal injection of 5–10 mg/kg diphenylpyrroline raises extracellular dopamine levels in the mouse nucleus accumbens by approximately 200 percent and causes mice to activate their locomotor system [2].
|
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice [2]
Doses: 5-10 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results:It has psychostimulant properties. |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Absorbed well after oral administration. Metabolism/Metabolites Liver |
| Toxicity/Toxicokinetics |
Protein Binding
99% Human Serum Albumin |
| References | |
| Additional Infomation |
Diphenylpyraline is a piperidine compound, a diphenyl methyl ether derivative of 1-methyl-4-hydroxypiperidine. It is a sedative antihistamine; its hydrochloride salt is used to relieve allergy symptoms, including rhinitis and hay fever, as well as to treat itchy skin conditions. It can also be used as an ingredient in combination preparations to relieve cough and common cold symptoms. It acts as both an H1 receptor antagonist and a cholinergic antagonist. It belongs to the piperidine class of compounds and is also a tertiary amine. Diphenylpyraline is an antihistamine. Antihistamines used to treat allergies act by competing with histamine for H1 receptor sites on effector cells. Antihistamines can prevent, but cannot reverse, reactions mediated solely by histamine. Antihistamines antagonize most of the pharmacological effects of histamine to varying degrees, including urticaria and pruritus. An allergen is a substance that causes an allergic reaction. See also: Diphenylpyraline hydrochloride (note moved to). Drug Indications Used to treat allergic rhinitis, hay fever, and allergic dermatitis. Mechanism of Action Antihistamines used to treat allergies, such as diphenylpyrrolidine hydrochloride, act by competing with histamine for H1 receptor sites on effector cells. This reduces the effect of histamine, thus temporarily relieving allergy symptoms. Pharmacodynamics Diphenylpyrrolidine hydrochloride is an antihistamine that prevents but does not reverse histamine-mediated reactions. Diphenylpyrrolidine antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Additionally, diphenylpyrrolidine may have anticholinergic effects (like most antihistamines) and may therefore cause dryness of the nasal mucosa.
|
| Molecular Formula |
C19H23NO
|
|---|---|
| Molecular Weight |
281.392
|
| Exact Mass |
281.178
|
| CAS # |
147-20-6
|
| Related CAS # |
132-18-3 (hydrochloride)
|
| PubChem CID |
3103
|
| Appearance |
White to off-white solid powder
|
| Density |
1.08 g/cm3
|
| Boiling Point |
378.7ºC at 760 mmHg
|
| Flash Point |
111.6ºC
|
| Vapour Pressure |
6.18E-06mmHg at 25°C
|
| Index of Refraction |
1.587
|
| LogP |
3.824
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
268
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OWQUZNMMYNAXSL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
|
| Chemical Name |
4-benzhydryloxy-1-methylpiperidine
|
| Synonyms |
AN1041; AN-1041; AN 1041
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~355.38 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.88 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5538 mL | 17.7689 mL | 35.5379 mL | |
| 5 mM | 0.7108 mL | 3.5538 mL | 7.1076 mL | |
| 10 mM | 0.3554 mL | 1.7769 mL | 3.5538 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
